Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes

Michel Delforge, Dominik Selleslag, Yves Beguin, Agnès Triffet, Philippe Mineur, Koen Theunissen, Carlos Graux, Fabienne Trullemans, Dominique Boulet, Koen Van Eygen, Lucien Noens, Steven Van Steenweghen, Jan Lemmens, Pascal Pierre, Randal D'hondt, Augustin Ferrant, Dries Deeren, Ann Van De Velde, Wim Wynendaele, Marc AndréRobrecht De Bock, André Efira, Dimitri Breems, Anne Deweweire, Kurt Geldhof, Wim Pluymers, Amanda Harrington, Karen MacDonald, Ivo Abraham, Christophe Ravoet

Research output: Contribution to journalArticle

46 Scopus citations

Abstract

Background: Most patients with myelodysplastic syndromes (MDS) require transfusions at the risk of iron overload and associated organ damage, and death. Emerging evidence indicates that iron chelation therapy (ICT) could reduce mortality and improve survival in transfusion-dependent MDS patients, especially those classified as International Prognostic Scoring System (IPSS) Low or Intermediate-1 (Low/Int-1). Methods: Follow-up of a retrospective study. Sample included 127 Low/Int-1 MDS patients from 28 centers in Belgium. Statistical analysis stratified by duration (≥6 versus <6. months) and quality of chelation (adequate versus weak). Results: Crude chelation rate was 63% but 88% among patients with serum ferritin ≥1000. μg/L. Of the 80 chelated patients, 70% were chelated adequately mainly with deferasirox (26%) or deferasirox following deferoxamine (39%). Mortality was 70% among non-chelated, 40% among chelated, 32% among patients chelated ≥6. m, and 30% among patients chelated adequately; with a trend toward reduced cardiac mortality in chelated patients. Overall, median overall survival (OS) was 10.2 years for chelated and 3.1 years for non-chelated patients (p< 0.001). For patients chelated ≥6. m or patients classified as adequately chelated, median OS was 10.5 years. Mortality increased as a function of average monthly transfusion intensity (HR. = 1.08, p= 0.04) but was lower in patients receiving adequate chelation or chelation ≥6. m (HR. = 0.24, p< 0.001). Conclusion: Six or more months of adequate ICT is associated with markedly better overall survival. This suggests a possible survival benefit of ICT in transfusion-dependent patients with lower-risk MDS.

Original languageEnglish (US)
Pages (from-to)557-563
Number of pages7
JournalLeukemia Research
Volume38
Issue number5
DOIs
StatePublished - May 2014

Keywords

  • Cardiac death
  • Chelation therapy
  • Iron overload
  • Myelodysplastic syndromes
  • Transfusion
  • Transfusion dependency

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes'. Together they form a unique fingerprint.

  • Cite this

    Delforge, M., Selleslag, D., Beguin, Y., Triffet, A., Mineur, P., Theunissen, K., Graux, C., Trullemans, F., Boulet, D., Van Eygen, K., Noens, L., Van Steenweghen, S., Lemmens, J., Pierre, P., D'hondt, R., Ferrant, A., Deeren, D., Van De Velde, A., Wynendaele, W., ... Ravoet, C. (2014). Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes. Leukemia Research, 38(5), 557-563. https://doi.org/10.1016/j.leukres.2014.02.003